<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->

<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].-->
{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
|-
|style="background-color:#F0F0F0|[[File:Jeenavarghese.jpg|frameless|upright=0.3|center]]
|<big>[[User:Jvarghese|Jeena M. Varghese, MBBS]]<br>Houston, TX</big><br>[https://www.linkedin.com/in/jeena-varghese-b2b45b9b/ LinkedIn]
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf NCCN Guidelines - Neuroendocrine Tumors]

=All lines of therapy=

==Cyclophosphamide, Dacarbazine, Vincristine {{#subobject:6ff914|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CVD: '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>D</u>'''acarbazine

===Regimen {{#subobject:5998d1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annals.org/article.aspx?articleid=702515 Averbuch et al. 1988]
|style="background-color:#ffffbe"|Pilot, <20 pts
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Dacarbazine (DTIC)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988 Aug 15;109(4):267-73. [http://annals.org/article.aspx?articleid=702515 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3395037 PubMed]

==<sup>131</sup>I-Metaiodobenzylguanidine (<sup>131</sup>I-MIBG) {{#subobject:57992a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Also known as m-[131I]iodobenzylguanidine ([131I]MIBG).

===Variant #1 {{#subobject:f474b2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.11518/full Rose et al. 2003]
|style="background-color:#ffffbe"|Pilot, <20 pts
|-
|}
''Patients underwent stem cell harvest prior to treatment in case autologous stem cell infusion was needed.''
====Radiotherapy====
*<sup>131</sup>I-Metaiodobenzylguanidine (<sup>131</sup>I-MIBG) 12 to 18 mCi/kg (maximum single dose of 850 mCi) IV over 2 hours once on day 1

====Supportive medications====
*Intravenous fluids started 12 hours before 131I-MIBG administration.
*Potassium iodide (KI) 6 mg/kg PO once at least 2 hours prior to 131I-MIBG, then potassium iodide (KI) 0.88 mg/kg PO Q4H x 7 days, then potassium iodide (KI) 1 mg/kg PO (frequency not specified) "for 45 days after the infusion."
*Potassium perchlorate 8 mg/kg once at least 2 hours prior to 131I-MIBG, then potassium perchlorate 2 mg/kg PO Q6H x 5 days.

'''"Repeat 131I-MIBG treatments were administered on a case-by-case basis in an effort to improve the overall response"'''

===Variant #2 {{#subobject:53e027|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jcem.endojournals.org/content/72/2/455.long Krempf et al. 1991]
|style="background-color:#ffffbe"|Pilot, <20 pts
|-
|}
====Radiotherapy====
*m-[131I]iodobenzylguanidine ([131I]MIBG) 740 megabequerel/mg every 3 months

===References===
# Krempf M, Lumbroso J, Mornex R, Brendel AJ, Wemeau JL, Delisle MJ, Aubert B, Carpentier P, Fleury-Goyon MC, Gibold C, Guyot M, Lahneche B, Marchandise X, Schlumberger M, Charbonnel B, Chatal JF. Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 1991 Feb;72(2):455-61. [http://jcem.endojournals.org/content/72/2/455.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1991814 PubMed]
# Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer. 2003 Jul 15;98(2):239-48. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.11518/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12872341 PubMed]

[[Category:Pheochromocytoma regimens]]
[[Category:Disease-specific pages]]
[[Category:Endocrine cancers]]
